{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Leslie", "organization": "", "rank": 1, "lastname": "PICKER"}], "original": "By LESLIE PICKER"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-thumbWide.jpg", "legacy": {"wide": "images/2016/04/07/business/07db-fees/07db-fees-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "401"}, "width": 600, "subtype": "xlarge", "height": 401}, {"type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"main": "Pfizer and Allergan Advisers Lose Out on $200 Million in Fees"}, "print_page": null, "keywords": [{"value": "Banking and Financial Institutions", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Antitrust Laws and Competition Issues", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Regulation and Deregulation of Industry", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "ALLERGAN INC", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Pfizer Inc", "is_major": "N", "rank": "6", "name": "organizations"}, {"value": "Halliburton Company", "is_major": "N", "rank": "7", "name": "organizations"}, {"value": "Baker Hughes Inc", "is_major": "N", "rank": "8", "name": "organizations"}], "snippet": "Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates.", "source": "The New York Times", "lead_paragraph": "Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates.", "word_count": "468", "pub_date": "2016-04-07T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/04/07/business/dealbook/pfizer-and-allergan-advisers-lose-out-on-200-million-in-fees.html", "_id": "5705573838f0d86865ca51b5"}